RecruitingNot ApplicableNCT04946916

Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease

Validation of Serum Neurofilament Light Chain as a Biomarker to Differentiate Cognitive Impairment From Neurodegenerative or Psychiatric Diseases

Sponsor

Hôpital le Vinatier

Enrollment

120 participants

Start Date

Oct 22, 2021

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease Schizophrenia Bipolar Disorder FTD

Summary

The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management. Neurofilaments, which are markers of neuronal lysis, appear to be a promising biomarker. In a previous preliminary study, the investigators demonstrated significantly lower concentrations of neurofilaments in CSF of psychiatric patients compared to neurodegenerative diseases. The main objective of this study is to validate the plasma assay of neurofilament light chain as a biomarker for the differential diagnosis of psychiatric or neurodegenerative cognitive impairment. Other biomarkers of interest (Tau, TDP-43, GFAP and UCH-L1) will also be analyzed. A sub-part of this study will also focus on the retrospective analysis of the CSF/Plasma correlations of the different biomarkers mentioned above from tube bottom samples taken in routine care.

Eligibility

Min Age: 45 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether a blood protein called neurofilament light chain (NfL) — a marker of nerve cell damage — can help predict or explain cognitive (thinking and memory) problems in people with long-term psychiatric conditions like schizophrenia and bipolar disorder, and whether the pattern differs from people with Alzheimer's disease or frontotemporal dementia. **You may be eligible if...** - You have a diagnosis of schizophrenia or bipolar disorder (with or without cognitive decline), OR a confirmed diagnosis of frontotemporal dementia or Alzheimer's disease - You are between 45 and 80 years old - You are able to provide informed consent **You may NOT be eligible if...** - You are unable to be interviewed or your medical history is incomplete - You have had a significant head injury with loss of consciousness - You have had a stroke (ischemic or hemorrhagic) - You have chronic alcoholism or ongoing drug use - You have a serious progressive physical illness, severe metabolic disorder, or poorly controlled epilepsy - You have received electroconvulsive therapy (ECT) within the last 6 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.